KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) Net Margin (2016 - 2025)

Ionis Pharmaceuticals has reported Net Margin over the past 17 years, most recently at 60.76% for Q4 2025.

  • Quarterly results put Net Margin at 60.76% for Q4 2025, up 10711.0% from a year ago — trailing twelve months through Dec 2025 was 5.76% (up 5870.0% YoY), and the annual figure for FY2025 was 0.02%, up 6444.0%.
  • Net Margin for Q4 2025 was 60.76% at Ionis Pharmaceuticals, up from 82.06% in the prior quarter.
  • Over the last five years, Net Margin for IONS hit a ceiling of 6177.55% in Q2 2025 and a floor of 119.5% in Q1 2024.
  • Median Net Margin over the past 5 years was 54.15% (2021), compared with a mean of 273.9%.
  • Biggest five-year swings in Net Margin: tumbled -40887bps in 2022 and later skyrocketed 620697bps in 2025.
  • Ionis Pharmaceuticals' Net Margin stood at 374.36% in 2021, then tumbled by -109bps to 34.52% in 2022, then skyrocketed by 92bps to 2.85% in 2023, then plummeted by -1524bps to 46.35% in 2024, then soared by 231bps to 60.76% in 2025.
  • The last three reported values for Net Margin were 60.76% (Q4 2025), 82.06% (Q3 2025), and 6177.55% (Q2 2025) per Business Quant data.